News

Fabrazyme helps ease Fabry disease symptoms in Chinese study

Treatment with Fabrazyme (agalsidase beta) for Fabry disease was safe and tolerated well over about a year, led to reductions in disease-related biomarkers, and eased symptoms in most patients, according to results of a post-marketing surveillance trial in China. An approved enzyme replacement therapy (ERT) for Fabry disease,…

Fabry can pose serious heart risk for women, men

Fabry disease takes a significant toll on the hearts of both male and female patients in Finland, often leading to cardiomyopathy, a serious heart condition, according to a recent study. This condition, which weakens the heart muscle, increases the risk of heart failure and stroke. Researchers also found a…